Search research articles
Contact Us
Filters
Showing results (1-10 of 10) with videos related to
Page
of 1
Sort By:
Therapeutic Advances in Hematology
|
August 20, 2015
Obinutuzumab for the treatment of patients with previously untreated chronic lymphocytic leukemia: overview and perspective
Carolyn J Owen, Douglas A Stewart
Expert Opinion on Biological Therapy
|
May 27, 2014
Obinutuzumab for B-cell malignancies
Carolyn J Owen, Douglas A Stewart
Blood and Lymphatic Cancer : Targets and Therapy
|
July 31, 2019
Blastic plasmacytoid dendritic cell neoplasm: challenges and future prospects
Amy M Trottier, Sonia Cerquozzi, Carolyn J Owen
Leukemia & Lymphoma
|
October 7, 2014
Comparative effectiveness analysis of different salvage therapy intensities used for diffuse large B-cell lymphoma in Northern or Southern Alberta: an instrumental variable analysis
Danielle H Oh, Sunita Ghosh, Neil Chua, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
January 20, 2016
Quantifying Benefit of Autologous Transplantation for Relapsed Follicular Lymphoma Patients via Instrumental Variable Analysis
Danielle H Oh, Haocheng Li, Qiuli Duan, et al.
Leukemia & Lymphoma
|
June 14, 2012
Proposal for the clinical detection and management of patients and their family members with familial myelodysplastic syndrome/acute leukemia predisposition syndromes
Jane E Churpek, Rachelle Lorenz, Siya Nedumgottil, et al.
Hemasphere
|
August 28, 2024
Long-term immune changes in patients with relapsed/refractory chronic lymphocytic leukemia following treatment with venetoclax plus rituximab
Arnon P Kater, Barbara F Eichhorst, Carolyn J Owen, et al.
Blood
|
August 30, 2008
Five new pedigrees with inherited RUNX1 mutations causing familial platelet disorder with propensity to myeloid malignancy
Carolyn J Owen, Cynthia L Toze, Anna Koochin, et al.
Blood
|
May 23, 2022
Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab
John F Seymour, Thomas J Kipps, Barbara F Eichhorst, et al.
The New England Journal of Medicine
|
January 10, 2014
Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions
Valentin Goede, Kirsten Fischer, Raymonde Busch, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 10) with videos related to
Sort By:
Page
of 1
Therapeutic Advances in Hematology
|
August 20, 2015
Obinutuzumab for the treatment of patients with previously untreated chronic lymphocytic leukemia: overview and perspective
Carolyn J Owen, Douglas A Stewart
Expert Opinion on Biological Therapy
|
May 27, 2014
Obinutuzumab for B-cell malignancies
Carolyn J Owen, Douglas A Stewart
Blood and Lymphatic Cancer : Targets and Therapy
|
July 31, 2019
Blastic plasmacytoid dendritic cell neoplasm: challenges and future prospects
Amy M Trottier, Sonia Cerquozzi, Carolyn J Owen
Leukemia & Lymphoma
|
October 7, 2014
Comparative effectiveness analysis of different salvage therapy intensities used for diffuse large B-cell lymphoma in Northern or Southern Alberta: an instrumental variable analysis
Danielle H Oh, Sunita Ghosh, Neil Chua, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
January 20, 2016
Quantifying Benefit of Autologous Transplantation for Relapsed Follicular Lymphoma Patients via Instrumental Variable Analysis
Danielle H Oh, Haocheng Li, Qiuli Duan, et al.
Leukemia & Lymphoma
|
June 14, 2012
Proposal for the clinical detection and management of patients and their family members with familial myelodysplastic syndrome/acute leukemia predisposition syndromes
Jane E Churpek, Rachelle Lorenz, Siya Nedumgottil, et al.
Hemasphere
|
August 28, 2024
Long-term immune changes in patients with relapsed/refractory chronic lymphocytic leukemia following treatment with venetoclax plus rituximab
Arnon P Kater, Barbara F Eichhorst, Carolyn J Owen, et al.
Blood
|
August 30, 2008
Five new pedigrees with inherited RUNX1 mutations causing familial platelet disorder with propensity to myeloid malignancy
Carolyn J Owen, Cynthia L Toze, Anna Koochin, et al.
Blood
|
May 23, 2022
Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab
John F Seymour, Thomas J Kipps, Barbara F Eichhorst, et al.
The New England Journal of Medicine
|
January 10, 2014
Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions
Valentin Goede, Kirsten Fischer, Raymonde Busch, et al.
Page
of 1